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Abstract 
 
Introduction: Malignant mesothelioma is a rare and lethal malignancy primarily affecting 
the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and 
current treatments remain ineffective, leading to poor prognosis. Within this article potential 
targets to improve the quality of life of the patients and assessment of further avenues for 
research are discussed. 
 
Areas covered: This review highlights emerging therapies currently under investigation for 
malignant mesothelioma with a specific focus on phase I and phase II clinical trials. Three 
main areas are discussed: immunotherapy (immune checkpoint blockade and cancer vaccines, 
among others), multitargeted therapy (such as targeting pro-angiogenic genes) and gene 
therapy (such as suicide gene therapy). For each, clinical trials are described to detail the 
current or past investigations at phase I and II. 
 
Expert opinion: The approach of applying existing treatments from other cancers does not 
show significant benefit, with the most promising outcome being an increase in survival of 
2.7 months following combination of chemotherapy with bevacizumab. It is our opinion that 
the hypoxic microenvironment, the role of the stroma, and the metabolic status of 
mesothelioma should all be assessed and characterised to aid in the development of new 
treatments to improve patient outcomes. 
 
Keywords: Malignant mesothelioma, immunotherapy, targeted therapy and gene therapy  
Highlights box 
 Since the success of immune checkpoint inhibitors and cancer vaccines approved by the 
FDA for the treatment of cancers such as melanoma, immunotherapy may be evaluated 
as a third-line therapy for cancer treatment after conventional treatments and targeted 
agents.  
 Mesothelin is one of the main targets in immunotherapeutic approaches but the efficacy 
of this strategy is still poor.  
 CTLA-4 and PD1/L1 blockage are widely investigated in numerous clinical trials as single or 
combined therapy in mesothelioma patients but the outcome is still unsatisfactory  
 Main targeted therapies against EGFR and VEGFA/VEGFR showed no clinical activity in 
mesothelioma patients and only slightly promising results have been shown in patients 
treated with bevacizumab in combination with chemotherapy.  
 It is our belief that to improve current therapies the role of the hypoxic microenvironment 
and influence of the stroma in chemoresistance should be further characterised, in 
addition to uncovering the extent of metabolic reprogramming that occurs in tumours 
cells. 
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1. Introduction  
 
Malignant mesothelioma (MM) is a lethal and rare malignancy arising from surface 
mesothelial cells lining cavities such as pleura (malignant pleural mesothelioma, MPM, 
approximately 80% of cases), peritoneum (approximately 20% of cases) whilst less than 1% 
of cases occur in the pericardium and tunica vaginalis 1, 2. The major common risk factor for 
MM is asbestos exposure but radiation and simian virus 40 (SV40) have also been implicated 
as additional risk factors for MM 3. Recently, it has been reported that BRCA1 associated 
protein-1 (BAP1) mutation could be a genetic predisposition to MM 4. MM is characterised 
by a long latency period (20-40 years) before the symptoms occur. The symptoms themselves 
are non-specific, which makes this tumour difficult to diagnose and the disease itself has a 
poor prognosis; the median survival rate is less than twelve months 5 and only 10-20% of 
cases present life expectancy of 5-years 6. The worldwide incidence rate is increasing and a 
peak is expected between 2015-2030. A study on mesothelioma frequency between 1994-
2008 reported a global average of 14,200 cases each year 7. The USA, UK, Australia and 
Italy all report high incidence rates. In industrialized countries, where asbestos is used 
illegally, the incidence frequency is expected to increase, thus affecting the global incidence 
8. There is generally a lack of curative treatments for MM patients. Systemic treatment in the 
form of chemotherapy, radiotherapy and targeted therapy are options as single treatment or in 
combination in a multimodality regimen 8. Surgery is debatable and is recommended only in 
patients with early stage disease and in a good general health. A number of novel therapeutic 
drugs are under investigation, and may provide further treatment options for MM in the 
future. In this review, we will summarise current clinical trials and highlight promising 
agents, giving an overall opinion from a translational research team. 
  
2. Novel Therapeutics Under Investigation for Mesothelioma   
 
There are 256 clinical trials for MM currently reported in ClinicalTrials.gov, including 
recruiting, completed, active and terminated studies as single intervention or in combination 
modality. The main categories of agents investigated include immunotherapeutics, gene 
therapy, and multiple targeted therapies.  Different approaches will be discussed in turn 
throughout this manuscript, in addition to describing phase I and phase II trials for them. 
 
 
2.1 Immunotherapy 
 
Recently, immunotherapy, including active and passive therapeutic strategies has acquired a 
significant interest in the field of cancer treatment. Active strategies utilise for example 
tumour-specific antigens to trigger a direct immune system response such as cancer vaccines 
9. Passive approaches use an activated immune cell effector component such as 
immunomodulators (including cytokines) and tumour-specific antibodies to target tumour 
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antigens without direct stimulation of the immune system 10, whilst adoptive cellular therapy 
aims to administer genetically modified immune cells directly to patients 11. For decades 
immunotherapy has reported clinical failures but recently the development of new molecules 
such as immune checkpoint inhibitors have shown promising results, leading to the approval 
of immune checkpoint inhibitors for the treatment of melanoma. Cytotoxic T-lymphocyte 
antigen 4 (CTLA-4; CD152) is a key immune checkpoint and serves to downregulate 
immune responses, as does programmed death-1/programmed death ligand-1 (PD-1/PDL-1). 
Antibodies such as ipilimumab and nivolumab have been developed against CTLA-4 and PD-
1 respectively and were approved for the treatment of melanoma in 2011 and 2014 
respectively 9. The most common use of immunotherapy is as part of combination therapy 
with other conventional and non-conventional approaches which aim to achieve enhanced 
efficacy with a diminished toxic effect, thus modulating a durable and adaptable cancer 
control response. Preclinical studies suggest a potential for synergistic effects on tumour 
response and overall survival (OS) in multimodality treatment with agents that target 
different immune checkpoints 12. However, combination immunotherapy against multiple 
checkpoints has also demonstrated a high rate of side-effects, such as one study combining 
nivolumab and ipilimumab for the treatment of melanoma which showed side-effects at grade 
three or four in 55% of patients 13. At present, immunotherapy is typically evaluated as a 
third-line for cancer therapy after conventional treatments and targeted agents. Trials relating 
to immunotherapy are summarised in Table 1 and Table 2.  
 
2.1.1 Cancer Vaccines 
 
The main aim of cancer vaccination is to educate immune system to recognise cancer cells, 
which exhibit specific tumour antigens, thereby restoring or promoting the ability of the 
immune system, mainly by CD8+ cytotoxic T cell activation, to fight cancer cells 14. Several 
subcategories of vaccines have been developed, detailed below in the subsequent sections. 
 
2.1.2 Dendritic-Cell-Based Vaccines  
 
A common approach in vaccine immunotherapy is the use of dendritic cells (DCs) loaded 
with tumour-associated antigens. DCs are a heterogeneous population of antigen-presenting 
cells (APCs) and are specialized in processing proteins, which leads to the subsequent 
presentation of antigens. Production of autologous DCs is carried out through ex vivo 
differentiation from peripheral blood precursors, followed by maturation of DCs to activate 
them 15. Before being injected in the patients DCs are loaded with tumour lysates derived 
from patients either via viral infection or grown in media containing antigenic peptides 16. 
Upon infusion into the patient, the activated DCs generate anti-tumour T-cell responses due 
to CD4+ T cells activating CD8+ effector T-cells (Fig 1). In April 2010, the FDA approved 
Sipuleucel-T (PROVENGE; Dendreon) as the first therapeutic cancer vaccine for use in 
patients who have metastatic castration-resistant prostate cancer 17. The success of this 
vaccine is related to the increase of OS, although the disease progression was unchanged, 
giving an additional treatment option for patients with prostate cancer 18. However, ex vivo 
5 
 
therapies such as PROVENGE had a limited practical use in other cancer types and produced 
an immune response with limited scope 19. 
 
2.1.3 Peptide or Protein-Based Vaccines 
 
 
Peptide/protein vaccines are based on the principle of stimulating CD8+ T cells to promote 
an anti-tumour effect, and consist of five broad categories:  mutated antigens expressed only 
by the tumours; overexpressed normal self-antigens; oncofoetal antigens which are present in 
foetal tissues as well as some adult tumours; differentiation or lineage antigens; and cancer-
testis antigens 20-22 (Fig 2). Among these, an interesting target is Wilms tumour gene (WT1) 
protein, which is highly expressed in various tumours, including mesothelioma and is 
associated with oncogenic function, providing a strong rationale to consider WT1 as an 
attractive target for cancer immunotherapy 23. An additional common target is mesothelin, a 
cell-surface antigen associated with tumour invasion, which is highly expressed in several 
solid tumours such as mesothelioma and has been targeted in immunotherapy approaches due 
to the fact that its expression is low in normal mesothelial cells. Cancer vaccines developed 
against mesothelin use a live attenuated Listeria monocytogenes-expressing mesothelin 
(CRS-207, JNJ-64041757). Numerous antigens with promising potential are under 
investigation in few cancers 24. 5T4 vaccine (TroVax®) targets an oncofoetal antigen called 
5T4 which is inserted in an attenuated modified vaccinia ankara (MVA) virus. 5T4 is 
upregulated in cancer with a limited expression in normal tissue and is associated with 
epithelial mesenchymal transition (EMT), contributing to metastasis of epithelial cancers 24. 
Thus, this represents an interesting target for therapeutic development. 
 
2.1.4 Phase I Clinical Trials 
 
A preliminary study on murine malignant mesothelioma model showed that immunotherapy 
using tumour lysate–pulsed dendritic cells controlled MM outgrowth 25. Following this a 
phase I study investigated the safety and immunological response after the administration of 
tumour lysate-pulsed dendritic cells in MPM patients. The results showed a well-tolerated 
profile, with the treatment inducing an immunological response to tumour cells in MPM 
patients (NCT00280982) 26. Further, to investigate whether the combination of low-dose 
cyclophosphamide with autologous tumour lysate–pulsed dendritic cells was advantageous 
compared to monotherapy, the effect of this combination on the suppressive function of 
regulatory T cells was assessed in 10 MPM patients. This approach demonstrated disease 
control and a well-tolerated profile (NCT01241682) 27. 
Another pilot study was designed to assess the safety profile and efficacy of tumour cell 
vaccines in combination with the chemotherapeutic compound cyclophosphamide and the 
anti-inflammatory drug celecoxib in patients with mesothelioma. The study has been 
completed and 10 patients have been enrolled but the data are not available yet 
(NCT01143545). An additional pilot study investigated the safety and immunogenicity profile 
of a WT1 vaccine in patients with thoracic neoplasms (mesothelioma and non-small cell lung 
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cancer (NSCLC)) expressing WT1 28. Each vaccine dose was prepared by mixing equal 
volumes of adjuvant Montandine 51 with 200 µg each of four different peptide sequences 
known to bind MHC molecules and stimulate T cell responses 28. 200 µg was chosen as it is a 
known safe and active concentration. Injection sites were pre-stimulated with sargramostim 
(GM-CSF, granulocyte-macrophage colony-stimulating factor) and vaccines were 
administered subcutaneously 28. The immune response was stimulated in most of the patients, 
showing the ability of T cells to exert a cytotoxic effect against WT-1 positive cells. 
Therefore, a randomized II phase trial has been planned 28. Phase I clinical trials have been 
recently completed or are still ongoing testing the safety of WT1-based vaccines 
(NCT00398138) which evaluate WT1 vaccination in conjunction with conventional 
chemotherapy (NCT02649829). The outcome of completed studies showed the vaccination 
promoted a tumour-specific immunity (both cellular and humoral) and was safe but a clinical 
response was not observed 29. A phase I study tested CRS-207 (vaccine targeting mesothelin 
which is widely expressed on cancer cells) with chemotherapy in 38 patients. The clinical 
outcome showed that CRS-207 was well-tolerated and in combination with pemetrexed and 
cisplatin showed an anti-tumour activity with 59% of patients achieving an objective partial 
response and median progression free survival (PFS) of 8.5 months (NCT01675765) 30. 
 
2.1.5 Phase II Clinical Trials 
 
A pilot study investigated the clinical effects of cyclophosphamide in combination with 
autologous or allogeneic tumour cell vaccines to treat patients with various advanced cancers 
including mesothelioma (NCT00002475). An ongoing phase II study is evaluating treatment 
with the WT-1 peptide vaccine in combination with Montanide/GM-CSF versus 
Montanide/GM-CSF alone in patients with MPM who have completed multimodality therapy 
(NCT01265433).  
 
Table 1: Examples of Phase I and II clinical trials for vaccine immunotherapy. 
ClinicalTrials.gov 
Identifier 
Phase Treatment 
Number of 
Patients 
NCT00280982 I 
Autologous dendritic 
cells 
10 
NCT01241682 I 
Autologous dendritic 
cells + low-dose 
cyclophosphamide 
10 
NCT01143545 I 
Tumour cell vaccine 
in combination with 
cyclophosphamide  
and the anti-
inflammatory drug 
10 
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celecoxib 
NCT00398138 I 
Wilms’ tumour-1 
(WT-1) vaccine, with 
injection sites being 
pre-stimulated by 
sargramostim (GM-
CSF) 
22 
NCT02649829 I/II 
Autologous dendritic 
cells loaded with WT-
1 antigen in 
conjunction with 
conventional 
chemotherapy 
Currently 
recruiting 
NCT01675765 I 
Cancer vaccine CRS-
207 (attenuated 
Listeria 
monocytogenes) with 
or without 
cyclophosphamide 
60 
NCT00002475 II 
Cyclophosphamide in 
combination with 
tumour cell vaccine 
40 
NCT01265433 II 
Either non-specific 
immunotherapy 
(montanide and 
sargramostim) or WT-
1 vaccine, montanide 
and sargramostim 
31 
 
2.1.6 Antibody-Based Therapies 
 
One extensively investigated approach to overcome the toxicity of currently-used 
chemotherapies is the use of monoclonal antibodies (mAbs), which have the ability to 
precisely target malignant cells overexpressing specific surface antigens 31 (Fig 3A). 
Rituximab (anti-CD20 mAb) is the first approved mAb for the treatment of cancer, raising the 
interest in the development of a number of actively pursued antibody (Ab)-based 
technologies, including immunotoxins, radioimmuno-therapeutics,  and immunoliposomes 32.  
The main antibodies tested in clinical trials target mesothelin such as immunotoxins and 
chimeric antimesothelin antibodies (i.e. amatuximab) 33. Antimesothelin immunotoxin 
SS1(dsFv)PE38 (SS1P) is a recombinant molecule with a murine antimesothelin variable 
antibody fragment (Fv) linked to PE38, a truncated portion of Pseudomonas exotoxin A. In 
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preclinical models, SS1P reduced mesothelin-expressing tumors, both alone and in 
combination  with chemotherapy and radiation therapy 34. Amatuximab (MORAb-009) is a 
chimeric monoclonal antibody with a high affinity for human mesothelin (KD = 1.5 nM) 33, 35. 
Preclinical studies showed that amatuximab induces cell-mediated cytotoxicity in tumour 
cells expressing mesothelin 36. Moreover, using toxicological analyses it has been 
demonstrated that amatuximab did not cause any adverse effects in mouse models 36. 
Anetumab ravtansine (BAY 94-9343) is another antibody under investigation in MPM 
patients overexpressing mesothelin. An in vitro study demonstrated that anetumab exerts 
potent and selective cytotoxicity against mesothelin-expressing cells 37. A model study 
reported that anetumab interacts with mesothelin-positive tumours and inhibits tumour 
growth in xenograft models 37. 
GC1008 is a human anti-TGFβ monoclonal antibody that counteracts all isoforms of TGFβ 
thereby preventing tumour growth and metastasis 38, 39 . Preclinical data of TGFβ blockade in 
animal models of MPM and in human MPM cell lines suggest that TGFβ inhibitors can be 
effective therapeutic agents. In addition, high levels of TGFβ were found in rat and murine 
MPM cells as well as in tumours and in pleural effusions of MPM patients 40. However, cost 
limitations, inadequate pharmacokinetics and tissue accessibility all contribute to the need for 
further investigation and improvement of this approach 41. 
 
2.1.7 Cytokine-Based Therapy  
Cytokine-based immunotherapy aims to stimulate a cytotoxic immune response which 
involves stimulation of non-specific natural killer cells or highly specific cells such as 
cytotoxic T cells or Tumour Infiltrating Lymphocytes 42 (Fig 3B). Interleukin-2 (IL-2) is the 
first cytokine successfully used in clinical therapy but a small proportion of cancers can 
benefit from this approach and a complete clinical response occurs rarely 43. Among 
immunotherapeutic cytokines investigated as potential treatments are interferons (α, β, γ), 
which lead to an immune response with a significant toxic effect against tumour cells 42. In 
MPM, INFγ may contribute to a direct cytotoxic effect on mesothelial cells and stimulate NK 
and macrophages 44 .  
 
2.1.8 Phase I Clinical Trials 
 
A phase I trial of SS1P (which exerts its effects via targeting of mesothelin and Pseudomonas 
exotoxin A) aimed to verify the side effects and best dose of this immunotoxin approach in 
treating patients with recurrent unresectable advanced solid tumours, including MPM 
(NCT00066651) 45. 24 patients with different cancer types (9 with pleural mesothelioma, 5 
with peritoneal mesothelioma and 2 with pleural-peritoneal mesothelioma) were enrolled and 
the clinical outcome of this single therapy presented a well-tolerated profile up to 25 μg/kg/d 
×10 and exhibited a modest clinical activity, with 75% of patients exhibiting immunogenicity 
and 21% receiving a second cycle. One patient had a partial response, twelve had stable 
disease, and eleven had progressive disease 45. Another clinical trial evaluated the safety and 
tumour response of SS1P in combination with pemetrexed and cisplatin in 24 patients with 
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advanced MPM. SS1P given with pemetrexed and cisplatin had a safe and well tolerated 
clinical profile and showed significant antitumor activity with a partial response in 60% of 
patients (NCT01445392) 46. A phase 1 study was conducted to assess the safest doses of 
amatuximab in patients with mesothelin-positive cancers (pancreatic, ovarian, mesothelioma 
and lung) (NCT00325494). Amatuximab exhibited a well-tolerated profile and the maximum 
tolerated dose (MTD) was chosen at 200 mg/m2 47. Another study investigated the dose-
limiting toxicity and estimated MTD involving 17 patients with mesothelin-positive cancer, 
including mesothelioma patients (NCT01018784). Amatixumab was well-tolerated and MTD 
was determined to be 200 mg/m2 in agreement with the study mentioned above 48. A 
completed study investigating treatment with INF-α combined with cisplatin, surgery and 
radiotherapy in 6 MPM patients has also been performed, though results are not yet published 
(NCT00003263).  
 
2.1.9 Phase II Clinical Trials 
 
An open-label multicentre clinical trial investigated amatuximab plus pemetrexed and 
cisplatin for the treatment of 89 MPM patients. PFS and overall response (OR) were the 
endpoints for this study (NCT00738582) 49. Due to amatuximab demonstrating a favourable 
safety profile, exploration in other mesothelin-expressing cancers may be justified. A Phase II 
investigation of GC1008 to assess the overall safety and effectiveness in 13 patients with 
MPM has also been performed, which demonstrated that the drug was generally well-
tolerated in MPM patients (NCT01112293). However, partial or complete radiographic 
responses were not achieved and stable disease was observed in only 3 subjects. Patients who 
produced anti-TGFβ antibodies had increased median OS (15 vs 7.5 months, p < 0.03) 40. 
 
2.1.10 Adoptive T Cell Therapy 
 
Adoptive immunotherapy uses genetically enhanced T cells to trigger a potent and tumour-
specific immune effect that affects small or large tumour burdens. The advantage of this 
approach is that it should avoid side effects and toxicities associated with standard 
approaches such as chemotherapy 50. T cells are engineered to express a tumour antigen by 
the integration of genes encoding conventional T-cell receptors (TCRs) or chimeric antigen 
receptors (CARs, receptors which may undertake MHC-independent targeting and thus 
combine the targeting specificity of antibodies and the cytotoxicity of T cells) 50, 51 (Fig 3C). 
One of the most attractive CAR T cell applications is targeting overexpressed mesothelin in 
solid tumours, including mesothelioma 34. It has been shown that adoptive transfer of 
engineered antimesothelin human CAR T cells regressed large human MPM xenograft 
tumors in immunodeficient mice in preclinical models 52. Alternatively, CAR T cells were 
used to target non-transformed stromal cells, which promote cancer. CAR T cells were 
directed against fibroblast activation protein (FAP), which is overexpressed on the surface of 
reactive tumor-associated fibroblasts 53. High level of FAP expression in tumour tissue of 
MPM patients has been reported highlighting the potential of using adoptive T-cell therapy as 
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an effective approach to treat MPM 53. Another class of adoptive immunotherapy is the use of 
tumour infiltrating lymphocytes (TILs) which are engineered in vitro with affinity T cell 
receptors against major tumour antigens. One application of TIL therapy is using TILs in 
combination with high-dose interleukin-2 which has demonstrated a activity in several 
clinical trials, showing durable clinical response rates near 50% or more, though toxicities 
and side effects associated with interleukin-2 treatment have also been observed 54, 55. 
2.1.11 Phase I Clinical Trials 
 
A clinical trial of CAR T cells targeting mesothelin is recruiting participants with metastatic 
cancers, including mesothelioma. The purpose of this study is to evaluate the safe number of 
enhanced T cells to infuse and effective doses in an estimated number of 136 subjects 
(NCT01583686). Another recruiting clinical trial aims to use redirected T cells against FAP to 
assess the safety of a fixed single dose by direct injection in the pleural effusion for patients 
(estimated number of six) with MPM not eligible for surgery (NCT01722149). A Phase I/II 
evaluating cell infusion after administration of cyclophosphamide and fludarabine with low-
dose interleukin-2 therapy is currently under investigation (NCT02414945). 
 
 
2.1.12 Immune Checkpoint Treatment  
 
 
Cytotoxic T-lymphocyte antigen 4 (CTLA-4; CD152) receptor and programmed death-
1/programmed death ligand-1 (PD1/PDL-1) are the major immune checkpoints targeted for 
clinical studies 56, 57 (Fig 3D). The biological role of immune checkpoints is to negatively 
regulate the immune response by downregulating T-cell function resulting in immune 
tolerance to self-antigens, and balancing the immune response 58, 59. CTLA-4 exerts its 
inhibitory signal through competition with its positive counterpart, CD28, for its ligand B7 59. 
A preclinical study reported that CTLA-4-deficient mice die due to lethal 
lymphoproliferation 60 whilst a later study showed that blockade of CTLA-4 did not cause 
lethal systemic autoimmunity and promoted an antitumour effect  61 This preclinical rationale 
justified the development of two main immune checkpoint blockers: ipilimumab (known as 
MDX-010 or BMS-734016; Yervoy™, Bristol-Myers Squibb, Princeton, NJ), a fully human, 
IgG1 monoclonal antibody (mAb) which binds CTLA-4. Ipilimumab was the first immune 
checkpoint blockage therapy approved for treatment of metastatic melanoma in 2011 62. 
Ipilimumab was also approved by the Food and Drug Administration (FDA) as adjuvant for 
stage III melanoma 62.  Tremelimumab (CP-675 206 or ticilimumab; Pfizer Inc, New York, 
NY, USA) is a humanized IgG2 mAb against CTLA-4 that has also been used in clinical 
trials, detailed below 63. 
 
Following the promising results of CTLA-4 blockage, other immune checkpoints such as the 
PD-1/PD-L1 pathway have been targeted. PD-1 is a negative regulator of T-cells since by 
interacting with the PD-L1 and the PD-L2 ligands limits their activity. Several therapeutic 
agents have been developed against PD-1 and PD-L1 but the development of autoimmune 
diseases has been observed in PD-1–deficient mice in preclinical studies 64. Nivolumab 
known also as MDX-1106, BMS-936558, and ONO-4538; Opdivo®, Bristol-Myers Squibb, 
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Princeton, NJ) is a humanized IgG4 mAb. Nivolumab has been approved by FDA for the 
treatment of Hodgkin lymphoma 65, unresectable or metastatic melanoma 66 and metastatic 
NSCLC 67. Another therapy targeting PD-1 which has been clinically tested is 
pembrolizumab (MK-3475, lambrolizumab; Keytruda®, Merck, Whitehouse Station, NJ) 
which is an IgG4 engineered humanized Ab, approved in 2014 for the treatment of metastatic 
melanoma 68 and in 2015 for NSCLC 69. 
Other drugs targeting PD-L1 such as atezolizumab (MPDL3280A; Tecentriq®, Genentech, 
Inc, South San Francisco, CA), an IgG1 humanized, engineered mAb, has also been 
developed. In October 2016 the FDA approved atezolizumab for NSCLC. Avelumab 
(MSB0010718C,EMD Serono, Rockland, MA)  is a fully human  IgG1 monoclonal PD-L1 
antibody. 
Recently, another component of the B7 family, called B7-H3 (CD276), has been shown to 
regulate the immune response being involved in the inhibition of the signalling of the T-reg 
cells. B7-H3 is over-expressed in a wide variety of solid tumour types 70. Enoblituzumab 
(MGA271,) is an Fc-optimized humanized IgG1 mAb that binds to B7-H3 and has also been 
used in clinical trials, detailed in subsequent sections. B7-H3 is a negative immune 
checkpoint and it has been shown that its blockage can promote an anti-tumour immune 
response 71 
All of these immune checkpoint blockage therapies have been or are under investigation in 
MPM in phase I or phase II studies as described below.  
 
2.1.13 Phase I  
 
Several phase I clinical trials have been designed to evaluate pembrolizumab in combination 
with standard chemotherapy, radiotherapy (NCT02959463) or novel strategies such as 
defactinib (a focal adhesion kinase (FAK) inhibitor) (NCT02419495 and NCT02758587). Some 
of them are currently recruiting and the main aim is to evaluate the safety of the combination 
of pembrolizumab in combination with standard chemotherapy (NCT02707666) in particular as 
a window of opportunity pilot trial of pembrolizumab in patients affected by resectable 
malignant pleural mesothelioma. One study is investigating the combination of 
pembrolizumab with an antiangiogenesis agent (nintedanib) since antiangiogenic therapy 
may synergize with immunotherapy, thus offering a benefit for the quality of life of patients 
with advanced solid tumours, including MPM (NCT02856425). First considerations about the 
clinical profile of pembrolizumab has been presented at the AACR Annual Meeting 2015 
with a phase Ib study (KEYNOTE-028: NCT02054806). Published data related to this clinical 
trial showed that only five patients (20%) had a partial response and thirteen (52%) had stable 
disease and sixteen patients (64%)  showed a treatment-related adverse event 72.  
The PD-L1 inhibitor avelumab is under investigation in a phase I study that is currently 
recruiting patients with solid tumours including malignant mesothelioma (JAVELIN Solid 
Tumor: NCT01772004). Investigational studies of combined immunotherapy approaches are 
currently recruiting patients and are a phase I study of a combination modality of ipilimumab 
with enoblituzumab in refractory cancers, including MM (NCT02381314). Another phase I 
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study evaluates the safety of enoblituzumab in combination with pembrolizumab in refractory 
cancers such as malignant mesothelioma (NCT02475213). 
 
2.1.14 Phase II Clinical Trials  
 
The success of ipilimumab and its approval for the treatment of metastatic melanoma, plus 
the promising clinical efficacy of immunotherapy in combination with other treatments, has 
led to the investigation of ipilimumab in two phase II studies in combination with nivolumab 
(NCT03048474 and NCT02716272). The combination treatment with two different immune 
checkpoint inhibitors may delay tumour progression in patients with unresectable malignant 
pleural mesothelioma. However, the central immune checkpoint tested in mesothelioma is 
tremelimumab which has been investigated mainly as single dose in three phase II studies. A 
phase II study of tremelimumab in patients with chemotherapy-resistant advanced malignant 
mesothelioma (NCT01649024) has been carried out. Tremelimumab showed an adequate 
safety and tolerability profile although only 29 patients were enrolled and no patients 
achieved  a complete response and only two patients (7%) exhibited a durable partial 
response (one of 6 months and one of 18 months) 73. Another phase II trial assessed the 
efficacy and safety of an intensified schedule of tremelimumab in patients with unresectable 
advanced malignant mesothelioma (NCT01655888). In this study, 3% (one patient) achieved a 
partial response and 38% (11 patients) achieved disease control rate. Gastrointestinal and 
dermatological effects, as well as fever, were the major adverse effects observed that were 
related to treatment 74. The results showed a well-tolerated and safe profile that led to the use 
of the same intensified schedule in an ongoing randomised, double-blind, placebo-controlled, 
phase 2b study (NCT01843374). Tremelimumab has been selected for a combined therapy with 
another immune checkpoint targeting PD-L1 (MEDI4736). Two clinical studies are currently 
recruiting participants (NCT02588131 and NCT02592551).  
Nivolumab is also under investigation in an ongoing phase II study as monotherapy in 
patients previously treated with chemotherapy with mesothelioma (NCT02497508). 
Preliminary data from 38 patients has been released; five patients had reported a partial 
response; 12 had stable disease and 17 progressive disease and grade 3 toxicity is reported in 
8 patients leading to discontinuation of the treatment 75. Recent recruiting clinical studies 
evaluate the activity of pembrolizumab as a monotherapy in malignant mesothelioma 
(NCT02399371 and NCT02628067) or in combination with cisplatin/pemetrexed 
(NCT02784171). Atezolizumab is under assessment in a recruiting phase II study in 
advanced solid tumours, including mesothelioma (NCT02458638).  
 
Table 2: Phase I and phase II clinical trials for other immunotherapeutic approaches. 
 
ClinicalTrials.gov 
Identifier 
Phase Treatment 
Number of 
Patients 
NCT00066651 I SS1(dsFv)-PE38 24 
13 
 
immunotoxin 
NCT01445392 I 
SS1(dsFv)-PE38 in 
addition to cisplatin 
and pemetrexed 
24 
NCT00325494 I Amatuximab 24 
NCT01018784 1 Amatuximab 17 
NCT00003263 I 
INF-α combined with 
chemotherapy, 
radiotherapy and 
surgery 
6 
NCT00738582 II Amatuximab 89 
NCT01112293 II GC1008 (anti-TGF) 14 
NCT01583686 I/II Anti-mesothelin CAR 
T cells 
Currently 
recruiting 
NCT01722149 I 
Redirected anti-FAP 
T cells 
Currently 
recruiting 
NCT02959463 I 
Adjuvant 
pembrolizumab after 
radiation therapy 
Currently 
recruiting 
NCT02419495 I 
Numerous (including 
pembrolizumab and 
selinexor) 
142 
NCT02758587 I/II 
Defactinib and 
pembrolizumab 
Currently 
recruiting 
NCT02707666 I 
Pembrolizumab in 
combination with 
cisplatin and 
pemetrexed 
Currently 
recruiting 
NCT02856425 I 
Nintedanib and 
pembrolizumab 
Currently 
recruiting 
NCT02054806 I Pembrolizumab 477 
NCT01772004 I Avelumab 
Currently 
recruiting 
NCT02381314 I 
Enoblituzumab in 
combination with 
ipilimumab 
Currently 
recruiting 
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NCT02475213 I 
Enoblituzumab in 
combination with 
pembrolizumab 
Currently 
recruiting 
NCT03048474 II 
Nivolumab and 
ipilimumab 
Currently 
recruiting 
NCT02716272 II 
Nivolumab 
monotherapy or 
nivolumab in 
conjunction with 
ipilimumab 
125 
NCT01649024 II Tremelimumab 29 
NCT01655888 II Tremelimumab 29 
NCT01843374 II Tremelimumab 658 
NCT02588131 II 
Tremelimumab in 
combination with 
MEDI4736 (anti-PD-
L1) 
Currently 
recruiting 
NCT02592551 II 
MEDI4736 or 
MEDI4736 in 
combination with 
tremelimumab 
Currently 
recruiting 
NCT02497508 II Nivolumab 33 
NCT02399371 II Pembrolizumab 
Currently 
recruiting 
NCT02628067 II Pembrolizumab 
Currently 
recruiting 
NCT02784171 II 
Pembrolizumab, 
cisplatin, pemetrexed 
Currently 
recruiting 
NCT02458638 II Atezolizumab 
Currently 
recruiting 
 
 
2.2 Multiple Targeted Therapies: Small Molecule and Antibody Approaches  
 
The increased understanding of molecular pathways involved in tumorigenesis allows for the 
development of valid rationales to specifically target malignant cells in solid tumours, 
including MPM (examples of trials of targeted therapies are listed in Table 3). It is well-
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known that proliferative signalling promotes tumour progression by releasing growth factors 
such as epidermal growth factor receptor (EGFR) which plays a pivotal role in proliferation 
and mediates cell growth by activating specific downstream pathways contributing to survival, 
differentiation, migration and adhesion. EGFR is part of the family of transmembrane tyrosine 
kinase receptors (TKRs), including platelet-derived growth factor receptors (PDGRs), 
fibroblast growth factor receptors (FGFRs) and vascular endothelial growth factor receptors 
(VEGFRs) 76. The discovery of the role of this family prompted the development of tyrosine-
kinase inhibitors (TKIs), small molecules able to target the intracellular tyrosine kinase 
residue such as gefitinib and erlotinib which target EGFR (Fig 4). 
In MPM, studies revealed that EGFR was overexpressed at the protein level in around 52% of 
MPM patients 77-79. The role of vascular endothelial growth factor (VEGF) and its receptor 
VEGFR has been identified in MPM, showing high levels of both molecules in tissue 
specimens 80. Numerous inhibitors have been designed and tested in MM for these targets 
such as vatalanib, sorafenib, nintedanib, axitinib and cediranib and have shown limited or 
absent levels of activity, resulting in a lack of clinical benefits 81, 82. The most promising 
treatment to interact with VEFG signalling is bevacizumab (Avastin), a humanized 
monoclonal antibody against VEGFA which was approved in the EU in 2005 for the treatment 
of many solid cancers such as NSCLC, colorectal carcinoma, renal cell, and ovarian 83-86 (Fig 
4).  
Moreover several small molecules acting as inhibitors have been developed for different 
pathways, including targets involved in epigenetic regulation of tumour suppressor genes, 
such as histone deacetylase (HDAC) inhibitors. The main agents tested in clinical trials are 
belinostat and vorinostat. Another strategy uses asparagine–glycine–arginine–human tumour 
necrosis factor α (NGR-hTNF) which is TNF-alpha fused with NGR. NGR is able to bind 
specifically an aminopeptidase N isoform overexpressed on tumour blood system 87, 88. FAK 
represents an encouraging target for MPM in particular due to its involvement in cancer stem 
cell (CSC) renewal 89. Recently reported targeted therapies include RNA as a therapeutic 
target using ranpirnase, which promotes  impaired protein synthesis and cell cycle arrest, 
leading to an antitumor activity 90.  Other targets and inhibitors include: heat shock protein 90 
(HSP90) inhibitor (ganetespib); enhancer of zeste homolog 2 (EZH2) inhibitor (tazemetostat); 
inhibitor of the MET receptor tyrosine kinase (tivantinib); CSC inhibitor 
(napabucasin/BBI608) and TargomiRs (a mimic microRNA treatment).  
  
2.2.1 Phase I Clinical Trials 
 
A phase I study investigated the clinical profile of vorinostat in advanced tumours, including 
13 patients with MPM 91. The results of this study demonstrated there was no improved 
survival with the use of this drug.  Although vorinostat has been tested in a phase III study as 
a second-line therapy, there was no improvement in OS and it cannot be suggested as an 
option for treatment for MPM patients in advanced stage 92. A phase I study of TargomiRs, 
the first  in human patients, has been designed to evaluate the best dose as second or third line 
treatment in 27 MPM and NSCLC patients (NCT02369198), though results are not yet 
published. 
16 
 
 
2.2.2 Phase II Clinical Trials 
 
Gefinitib (ZD1839, Iressa) is the main TKI studied in a clinical trial involving 40 malignant 
mesothelioma patients with unresectable disease but did not show any clinical benefit despite 
the fact that 97% of patients overexpressed EGFR (NCT00025207) 93. Erlotinib, another TKI, 
did not improve survival in a study when used as a single agent in untreated patients 94.  
Promising results have been reported from a study of erlotinib in combination with 
bevacizumab in pre-treated patients, showing a stable disease in 50% of patients, a PFS of 2.2 
months and a median survival of 5.8 months (NCT00137826) 95. Bevacizumab, one of the 
most promising anti-VEGF therapeutic agents, has been tested in combination with cisplatin 
plus gemcitabine in a multicentre study involving 108 chemo-naïve mesothelioma patients. 
PFS was 6.9 months for the bevacizumab arm versus 6 months for the placebo and OS was 
improved by only 1 month (15.6mo vs 14.7mo) (NCT00027703). From these data, the 
conclusion is that bevacizumab does not improve PFS and OS 96. However, an additional 
phase III study showed that bevacizumab in combination with pemetrexed and cisplatin 
improved OS by 2.7 months relative to pemetrexed and cisplatin alone 97. A study of 
belinostat has been performed in patients with relapsed MPM but did not show activity in 
patients (NCT00365053) 98. Defactinib (VS-6063) is a potent selective FAK inhibitor. A 
phase II randomized multicenter trial (COMMAND) of defactinib in previously treated MPM 
was initiated but the study has been terminated due to the lack of evidence that it is efficient 
(NCT01870609). 
 
 
2.3   Gene Therapy 
 
Another therapeutic approach under investigation for MPM is gene therapy which consists of 
the transfer of genetic material in cells for therapeutic purposes. In MPM, several genes have 
been detected to be interesting targets for gene therapy and different types of delivery 
systems have been clinically investigated to assess safety and activity in MPM patients 99. 
MPM represents a promising target for gene therapy since the MPM tumour lining to the 
pleural cavity makes it easy to reach using in vivo gene delivery 100. Although these trials 
have demonstrated good safety results, there has been relatively limited efficacy 101. 
 
2.3.1 Suicide Gene Therapy 
 
Suicide gene therapy uses viruses to deliver a transgene which encode for a specific enzyme 
that is able to transform a prodrug into toxic metabolites, leading to tumour cell death or 
“suicide” 102. The most commonly investigated  approach is herpes simplex virus-1 thymidine 
kinase (HSVtk) gene which sensitises transduced cells to the nucleoside nontoxic antiviral 
drug ganciclovir 99 (Fig 5A). 
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2.3.2 Cytokine Gene Therapy 
 
Cytokine gene therapy is a promising treatment since it has the ability to activate systemic, 
intrapleural, and intratumoral immune effector cells. Cytokine gene therapy is an improved 
technique to express increased amount of cytokines (such as IL-2, IL-12, TNF or INF -α, β, 
or γ) using a viral vector with the advantage to reduce toxicity and increase the local 
concentration 103 (Fig 5B). 
 
2.3.3 Phase I Clinical Trials 
 
Clinical trials assessing gene therapy for mesothelioma have been designed. One study tested 
transgene expression and clinical profiles in MPM patients receiving high-dose adenovirus 
HSVtk/ganciclovir suicide gene therapy 104. The intrapleural administration was safe and 
well-tolerated in 34 patients but in only 2 patients long-term durable responses to the 
treatment were evident. Another study assessed the gene transfer,  immune response profile 
and tumour response of single-dose intrapleural IFN-β gene transfer using an adenoviral 
vector (Ad.IFN-β) in 10 mesothelioma patients, the results of which showed immune 
responses at a high rate 105. A clinical trial testing adenoviral-mediated IFN-β gene as a 
monotherapy for MPM patients is ongoing (NCT00299962). The first one is investigating two 
doses of the treatment whilst the second is a dose-escalation study. Currently an ongoing 
study “Autologous Redirected RNA Meso-CIR T Cells” is evaluating the safety and potential 
of Meso-CIR T cells (autologous chimeric immune receptor T cells that have been 
transfected with an anti-mesothelin mRNA) in 18 patients (NCT01355965). 
 
Table 3: Phase I and II clinical trials for targeted and gene therapies. 
 
ClinicalTrials.gov 
Identifier 
Phase Treatment 
Number of 
Patients 
NCT00025207 II 
Gefitinib (EGFR 
inhibitor) 
40 
NCT00137826 II 
Bevacizumab (VEGF 
inhibitor) and 
erlotinib (EGFR 
inhibitor) 
37 
NCT00027703 II 
Chemotherapy with or 
without bevacizumab 
106 
NCT00365053 II 
Belinostat (HDAC 
inhibitor) 
13 
18 
 
NCT01870609 II 
Defactinib (FAK 
inhibitor) 
344 
NCT00299962 I 
Adenoviral-mediated 
IFNβ 
18 (estimated, 
study ongoing) 
NCT01355965 I 
Redirected RNA 
Meso-CIR 
Autologous T Cells 
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3. Expert Opinion  
There is no doubt that in the last few years more effort has been placed in developing and 
testing new therapeutic options for mesothelioma. Unfortunately the major weakness of this 
(welcome) interest has been the idea that therapies with some activity for other tumours could 
be applied “tout court” to mesothelioma. It is clear that this approach is not based on a solid 
understanding of mesothelioma biology and it is questionable that it islikely to achieve 
significant results. 
Among others factors, it is our opinion that taking the hypoxic microenvironment of 
mesothelioma into account can assist in the development of much more “mesothelioma 
tailored” therapies 106. With regard to what the clinical trials for mesothelioma so far have 
shown as  the “best result” underpinning the front line therapy for this neoplasm is based on a 
trial that allows a gain of survival of 2.7 months and  on a preclinical study previously 
published by our group 97, 107. 
Hence rather than discussing what the most promising results of treatment for this tumour 
have been so far we should ask ourselves why we have not achieved more significant steps 
forward yet. A more precise focus on mesothelioma biology (encompassing genetics, 
metabolomics and functional studies) conducted on cell models closer to the in vivo events in 
primary tumour cell lines and 3D studies could foster our clinical impact. It is clear that 
surrogate end points such as progression-free survival do not mirror the real clinical effect of 
any novel treatment in oncology 108. Our purpose should be that of extending mesothelioma 
patient survival by longer than three months. 
This is particularly true for immunotherapy as recently demonstrated by the failure of clinical 
trials for mesothelioma with OS as a primary end point (in spite of some efficacy of the phase 
II trials) and, more generally, by the low number of patients who can truly benefit from 
immune checkpoint inhibitors. Moreover, the purely “genetic” approach to cancer treatment 
is currently being discussed and evaluated. This approach is even more contentious when one 
looks at the low mutational load of MPM 108, 109. 
 
We believe that only a more integrated and balanced approach to MPM will allow us to get 
ahead and achieve more significant clinical results. This should encompass multiple 
disciplines such as genetics, biochemistry and immunology that are already applied to cancer 
research and be even more focused on MPM than done so far. A more precise understanding 
of how the stroma may affect the response to therapy is also an important area and offers a 
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novel therapeutic target 53, 110. The effect of the microenvironment and the subsequent MPM 
metabolic reprogramming offers a unique scenario with potentially significant therapeutic 
implications for this orphan disease (manuscript in preparation). 
Ultimately magic bullets do not exist in oncology but we are confident that an unbiased 
multidisciplinary approach to this tumour could allow us to achieve significant results sooner 
than expected. Metabolic reprogramming of tumour cells, the hypoxic microenvironment and 
the stroma are all areas that offer promising points of interest for therapeutic development. 
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Figure 1. Passive Immunotherapy: Dendritic cell-based vaccines are developed by isolating immature 
dendritic cells from the patient and incubating them ex- vivo with tumour lysate. Mature DCs are 
injected back to the same patient to induce a tumour-specific immune response by activating tumour-
specific CD8+ T cells. 
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Figure 2. Peptide-based vaccines are single peptides or a cocktail of peptides obtained from cancer cells 
of patients and are amplified ex-vivo. These peptides are conjugated to an adjuvant and are injected 
back to the patient. DCs endocytose these peptides and present them and activate CD4+ cells which 
subsequently induce CD8+ CTL specific anti-tumour immune response. 
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Figure 3: Schematic representation of passive immunotherapeutic strategies. A) antibody-based strategy 
using monoclonal antibodies or immunotoxins against cancer cells (mesothelin is the main target for 
mesothelioma). B) Cytokine-based therapy provides cytotoxic immune response by activating natural 
killer (NK) cells or tumour-specific cytotoxic T cells. C) Adoptive T cells therapy uses engineered T cells 
expressing T-cell receptor (TCR), Tumour infiltrating lymphocytes (TIL) combined with interleukin-2 or a 
chimeric antigen receptor (CAR) to interact with cancer cells; D) In immune checkpoint blockade 
approach monoclonal antibodies specifically recognizing receptors such as the cytotoxic T-lymphocyte 
antigen 4 (CTLA-4) receptor or the programmed death-1/programmed death ligand-1 (PD1/PDL-1) are 
used to block the function of these receptors. 
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Figure 4. Graphic representation of anticancer multiple targeted approaches in MM. Belinostat and 
vorinostat induce DNA damage whereas the antibodies bevacizumab, gefitinib and erlotinib prevent the 
binding of VEGF and EGF respectively to their receptors thereby inhibiting their intracellular signalling. 
Bevacizumab functions extracellularly whereas the small molecules sorafenib and vatalanib inhibit the 
VEGFR intracellular signalling. 
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Figure 5. Summary of gene therapies for MM treatment. A) Suicide gene therapy: tumour cells modified 
to express a specific enzyme to metabolise a prodrug into a cytotoxic product to induce tumour cell 
death; B) Cytokine gene therapy: expression of cytokines to activate a more effective immune response. 
 
 
